Kringle Pharma (4884) set terms for a third-party allotment of 945,100 new shares at ¥529 each plus two series of warrants, aiming to raise an estimated net ¥2,206,176,550 if all warrants are exercised at initial prices.
The board approved the issuance on Nov. 11, 2026, and fixed the terms on Nov. 18. The new shares, totaling ¥499,957,900, will go to Maruishi Pharmaceutical (567,100 shares) and Zenoaq Holdings (378,000 shares), subject to the securities registration taking effect.
Macquarie Bank Limited will receive 21,460 warrants, 10,730 each in the 19th and 20th series, for a total issue price of ¥5,418,650 (¥270 and ¥235 per unit). Each unit converts into 100 shares, for 2,146,000 potential shares. The 19th series has a fixed exercise price of ¥600. The 20th series starts at ¥1,000; the board may elect to reset it to 92% of the prior trading day's close, with a floor of ¥260.
Total payments are estimated at ¥2,222,176,550, less ¥16 million in issuance costs. Planned uses, in millions of yen:
| Use | Amount |
|---|---|
| U.S. Phase III preparation, acute spinal cord injury | 678 |
| Production setup for recombinant human HGF protein API via new method | 640 |
| Domestic API manufacturing | 310 |
| Working capital | 578 |
The company ranked spending priority as the U.S. trial, domestic API, working capital, then the new production method. Funds are to be spent from December 2026 through September 2028 and held in bank accounts until then.
Next steps: payment for the shares and allotment of the warrants are set for Dec. 7, 2026; the warrant purchase agreement with Macquarie will be signed after the registration takes effect.
| I-ne | |
| Tender offer price | ¥2,248 per share |
| Kadoya Seiyu | |
| Tender offer price | ¥2,655 per share |
| TKP Corporation | |
| Effective date | March 1, 2027 (scheduled) |
| M3, Inc. | |
| Tender offer price | ¥1,619 per share |
| Digital Hearts Holdings | |
| Consolidation ratio | 2,975,211 shares into 1 share |
| Shoei Corporation | |
| Shares transferred | 1.8 million shares |
| TOSE Co., Ltd. | |
| Effective date (scheduled) | Jan. 4, 2027 |
| NSK Ltd. | |
| Share transfer ratio (NSK:NTN) | 1:0.353 |
| M&A / TOB | 20 |
| Guidance | 7 |
| Buybacks | 11 |
| Dividends | 4 |
| Capital | 12 |
| Earnings | 16 |
| People | 3 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。